Ascendis Pharma A/S ( (ASND) ) has released its Q3 earnings. Here is a breakdown of the information Ascendis Pharma A/S presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascendis Pharma A/S is a global biopharmaceutical company headquartered in Copenhagen, Denmark, focused on developing innovative therapies using its TransCon technology platform to address unmet medical needs.
In the third quarter of 2025, Ascendis Pharma reported significant revenue growth, driven by the successful global launch of YORVIPATH and the steady performance of SKYTROFA. The company achieved an operating profit of €11.0 million, marking a positive shift in its financial profile.
Key financial highlights include a total revenue of €213.6 million for the quarter, a substantial increase from €57.8 million in the same period last year. YORVIPATH contributed €143.1 million to the revenue, while SKYTROFA added €50.7 million. The company also noted a net loss of €61.0 million, a reduction from the previous year’s loss, and an increase in cash reserves to €539 million.
Strategically, Ascendis is advancing its pipeline with TransCon CNP under FDA priority review and plans for label expansions for both YORVIPATH and SKYTROFA. The company is also progressing with trials for various indications, including hypoparathyroidism and growth hormone deficiencies.
Looking ahead, Ascendis Pharma remains focused on its Vision 2030, aiming to continue its growth trajectory by expanding its product offerings and leveraging its TransCon technology to develop new therapies. The management anticipates sustainable growth driven by ongoing innovation and strategic market expansions.